

FIG. 1A




FIG. 1B




FIG. 1C





FIG. 1D



fraction maximal binding




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B






FIG. 3C

FIG. 3D










FIG. 3F

IFN gamma response of
BR4.2 T cells stimulated with B10.BR:MBP Ac1-16 +/-
HIV-TAT or CD3-TAT peptides @ 10uM









FIGURE 5



**Competition for Binding to Tax 1-IP:
The C-terminal 8 amino acids of Tax 1 Block Binding
of 20uM of the Labeled C-terminal 20 amino acids of CD95 (Fas)**




Fig. 6

**Competition for Binding to Tax 1-IP:
The C-terminal 8 amino acids of CD95 Block Binding
of 1 μ M of the Labeled C-terminal 20 amino acids of Tax 1**




Fig. 7

**Inhibition of Binding of 125 I-Biotin Labeled Peptide C
responding to the C-terminal 20 amino acids of BLR-1
to KIAA0807:GST Fusion Protein by Peptide
and Small Molecule Antagonists**




Fig. 8

**Inhibition of Binding of 100kDa Biotin Labeled Peptide
C respp nding t the C-terminal 20 amino acids of DOCK2
to KIAA0807:GST Fusion Protein by Peptide
and Small Molecule Antagonists**




Fig. 9